ATLANTA, GA – – (Globe Newswire – December 30, 2024) – – A shareholder class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts about Caribou’s business, operations, and prospects, including allegations that: (i) they overstated CB-010’s safety, efficacy, and durability relative to approved autologous chimeric antigen receptor-T (“CAR-T”) cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (ii) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-natural killer platform; and (iii) all the foregoing was likely to have a significant negative impact on Caribou’s business and operations.

If you bought shares of Caribou between July 14, 2023 and July 16, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/caribou-biosciences/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is February 24, 2025.